实体瘤癌症患者的阿片类药物使用与过量
该研究为加拿大安大略省基于人群的回顾性队列,纳入2013年1月1日至2020年12月31日新诊断实体瘤成人554316例,随访至首次阿片过量事件、死亡或2024年12月31日。结果显示1591例(0.3%)发生至少1次非致死性过量,191例(0.03%)发生致死性过量。诊断后第一年,III期和IV期癌症患者的任何阿片过量发生率显著高于I期(III期vs I期 HR 2.55,95%CI 1.96-3.31;IV期vs I期 HR 6.24,95%CI 4.68-8.31)。调整后,过去30天内任何阿片处方与合并非致死性和致死性过量率升高71%相关(HR 1.71,95%CI 1.47-2.00),高剂量(≥50 mg吗啡当量/日)处方者约为3.5倍(HR 3.47,95%CI 2.97-4.05)。作者建议以最低有效剂量处方阿片进行症状管理,并密切监测和常规评估阿片过量风险。
要点
- 实体瘤成人中阿片过量总体罕见:非致死性1591/554316(0.3%),致死性191/554316(0.03%)。
- 诊断后第一年,III期vs I期癌症任何阿片过量HR 2.55(95%CI 1.96-3.31),IV期vs I期HR 6.24(95%CI 4.68-8.31)。
- 过去30天内任何阿片处方与合并非致死性和致死性过量率升高71%相关(HR 1.71,95%CI 1.47-2.00)。
- 高剂量阿片(≥50 mg吗啡当量/日)处方者合并过量率约为无处方者的3.5倍(HR 3.47,95%CI 2.97-4.05)。
- 无阿片使用障碍的癌症患者中,近期任何剂量阿片处方HR 1.80(95%CI 1.54-2.11),高剂量HR 3.76(95%CI 3.21-4.41)。
适用人群与场景
- 加拿大安大略省新诊断实体瘤癌症的成人,基于ICES链接数据,纳入时间为2013年1月1日至2020年12月31日。
研究设计与关键结果
- 研究类型:基于人群的回顾性队列研究,样本量554316例成人实体瘤癌症患者。
- 主要结局:致死性或首次非致死性阿片过量事件;非致死性过量1591例(0.3%),致死性过量191例(0.03%)。
- 诊断后第一年,III期vs I期癌症任何阿片过量HR 2.55(95%CI 1.96-3.31),IV期vs I期HR 6.24(95%CI 4.68-8.31)。
- 调整后,过去30天内任何阿片处方与合并非致死性和致死性过量率升高71%相关(HR 1.71,95%CI 1.47-2.00)。
- 高剂量阿片(≥50 mg吗啡当量/日)处方者合并过量率HR 3.47(95%CI 2.97-4.05)。
- 无阿片使用障碍患者中,近期任何剂量阿片处方HR 1.80(95%CI 1.54-2.11),高剂量HR 3.76(95%CI 3.21-4.41)。
- 每持续每月高剂量阿片处方,阿片过量风险增加。
证据类型、等级与局限
- 证据类型:基于人群的回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,阿片应以最低有效剂量用于症状管理,并密切监测和常规评估阿片过量风险。
- 对晚期癌症(III/IV期)及诊断后第一年患者,处方阿片时需关注过量风险,高剂量(≥50 mg吗啡当量/日)处方与更高过量风险相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Opioids are essential for symptom control, but few studies have evaluated the association between prescription opioids and opioid overdose in oncology.
OBJECTIVE: To describe opioid overdose in adults with solid tumor cancers and examine how opioid overdose rates vary by patient factors, cancer characteristics, and opioid prescribing.
DESIGN, SETTING, AND PARTICIPANTS: This population-based, retrospective cohort study of adults in Ontario, Canada, used linked ICES data from January 1, 2013, to December 31, 2020. Participants entered the cohort at the time of newly diagnosed solid tumor cancers and were followed up from diagnosis to the first opioid overdose event, death, or December 31, 2024. Data analysis was performed from August to December 2025.
EXPOSURE: Exposure was outpatient opioid prescription dose and duration reassessed every 30 days.
MAIN OUTCOMES AND MEASURES: The primary outcome was a fatal or the first nonfatal opioid overdose event.
RESULTS: Among 554 316 adults with cancer (mean [SD] age, 63.8 [16.2], 57.1 [17.2], and 45.8 [13.7] years for the no, nonfatal, and fatal opioid overdose groups, respectively; 308 903 [55.9%], 921 [59.5%], and 116 [60.7%] female for the no, nonfatal, and fatal opioid overdose groups, respectively), 1591 (0.3%) had 1 or more nonfatal opioid overdoses, and 191 (0.03%) had a fatal opioid overdose. In the first year after diagnosis, patients with stage III and IV cancers had substantially higher rates of any opioid overdose than those with stage I (stage III vs I: hazard ratio [HR], 2.55; 95% CI, 1.96-3.31; stage IV vs I: HR, 6.24; 95% CI, 4.68-8.31). After adjustment, any opioid prescription in the prior 30 days was associated with 71% higher combined nonfatal and fatal opioid overdose rate (HR, 1.71; 95% CI, 1.47-2.00), and approximately 3.5 times higher if prescribed high-dose opioids (≥50-mg morphine-equivalent daily dose; HR, 3.47; 95% CI, 2.97-4.05). Recently prescribed opioids were associated with increased opioid overdose risk in patients with cancer without opioid use disorder (any dose: HR, 1.80; 95% CI, 1.54-2.11; high dose: HR, 3.76; 95% CI, 3.21-4.41).
CONCLUSIONS AND RELEVANCE: In this cohort study of adults with solid tumor cancers, opioid overdose was rare and highest in the first year after diagnosis and in patients with advanced cancer; opioid overdose risk increased with every month high-dose opioids were prescribed. The findings suggest that opioids should be prescribed at the lowest effective dose for symptom management, with close monitoring and routine assessment for opioid overdose risk.
参考来源
- Marret L, Gomes T, Everett K, et al. Opioid Use and Overdose in Patients With Solid Tumor Cancers. JAMA Netw Open. 2026. PMID: 43007672. doi:10.1001/jamanetworkopen.2026.42997
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。